Market Overview:
The global hydroxycarbamide market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Hydroxycarbamide is used for the treatment of sickle cell disease, cancer, and other conditions. The growth in this market can be attributed to factors such as rising prevalence of sickle cell disease and cancer, increasing demand for generic drugs, and growing awareness about hydroxycarbamide. However, the high cost of treatment may restrain the growth of this market in some regions.
Product Definition:
Hydroxycarbamide is also called “hydroxyurea” and it is a medication used to treat different types of cancer, sickle cell anemia, and other conditions.
Capsule:
Capsule is a small package containing medicine substance. It's main function is to protect drug from damage and oxidation, thus helping it to reach target location in the body. Capsules are widely used by pharmaceutical companies for packing medicines that need to be taken by mouth.
Hydroxycarbamide (HCA) or carbamide capsules are used as an ingredient in the treatment of cancer.
Tablet:
Tablet is a form of oral drug delivery system which comprises of an inert core containing the active pharmaceutical ingredient and surrounding layers of polymers. It is available in different sizes, shapes, and colors. The tablet consists of two parts namely the coating and the core part where coating contains disintegrants such as starch or other excipients along with active pharmaceutical ingredients (APIs).
Application Insights:
The other application segment includes diabetes, cancer and others. Hydroxycarbamide is used for the treatment of sickle cell disease, a rare genetic blood disorder that affects about 1 in 500 African Americans. The drug reduces the pain and inflammation caused by this chronic condition. It also helps in improving the overall quality of life for patients suffering from it.
Hydroxycarbamide is also used to treat various cancers such as pancreatic cancer, liver & biliary system cancer, breast & prostate cancer and others. However, its use in treating these diseases is not approved by the U.S FDA yet; hence its consumption remains limited to clinical trials purposes only till date.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of hydroxycarbamide manufacturers and suppliers coupled with high healthcare expenditure, favorable reimbursement policies for sickle cell disease treatment, and increasing awareness about hydroxycarbamide-based drugs are some factors responsible for its largest share.
Asia Pacific is expected to be the fastest-growing region over the forecast period owing to rising disposable income levels in emerging countries such as China and India. Moreover, growing investments by major pharmaceutical companies in this region will drive growth further due to availability of a large patient pool that requires drug therapy. In addition, improving healthcare infrastructure is also likely to contribute toward regional growth over the next eight years.
Growth Factors:
- Increasing prevalence of sickle cell anemia: The increasing prevalence of sickle cell anemia is one of the major growth drivers for the hydroxycarbamide market. Hydroxycarbamide is used as a treatment for this condition.
- Rising awareness about hydroxycarbamide: There is a growing awareness about the benefits of hydroxycarbamide among patients and healthcare professionals. This is likely to boost demand for this drug in the coming years.
- Growing number of clinical studies on hydroxycarbamide: A growing number of clinical studies on hydroxycarbamide are being conducted across the world, which is likely to create new opportunities for this market in the near future.
- Launch of novel formulations and products: Several pharmaceutical companies are launching novel formulations and products based on hydroxycarbamide, which is expected to fuel growth in this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hydroxycarbamide Market Research Report
By Type
Capsule, Tablet
By Application
Sickle Cell Disease, Cancer, Other
By Companies
Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, Khandelwal Laboratories, Alkem (Cytomed), Samarth Pharma, VHB Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Hydroxycarbamide Market Report Segments:
The global Hydroxycarbamide market is segmented on the basis of:
Types
Capsule, Tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Sickle Cell Disease, Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb
- Taj Pharma
- Beijing Jialin Pharma
- Qilu Pharmaceutical
- Teva Pharma
- Cipla
- Zydus Cadila
- United Biotech
- Par Pharma
- Khandelwal Laboratories
- Alkem (Cytomed)
- Samarth Pharma
- VHB Life Sciences
Highlights of The Hydroxycarbamide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Tablet
- By Application:
- Sickle Cell Disease
- Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hydroxycarbamide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hydroxycarbamide is a medication used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major players in the hydroxycarbamide market are Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, Khandelwal Laboratories, Alkem (Cytomed), Samarth Pharma, VHB Life Sciences.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hydroxycarbamide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hydroxycarbamide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hydroxycarbamide Market - Supply Chain
4.5. Global Hydroxycarbamide Market Forecast
4.5.1. Hydroxycarbamide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hydroxycarbamide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hydroxycarbamide Market Absolute $ Opportunity
5. Global Hydroxycarbamide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hydroxycarbamide Market Size and Volume Forecast by Type
5.3.1. Capsule
5.3.2. Tablet
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hydroxycarbamide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hydroxycarbamide Market Size and Volume Forecast by Application
6.3.1. Sickle Cell Disease
6.3.2. Cancer
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hydroxycarbamide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hydroxycarbamide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hydroxycarbamide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hydroxycarbamide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hydroxycarbamide Demand Share Forecast, 2019-2026
9. North America Hydroxycarbamide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hydroxycarbamide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hydroxycarbamide Market Size and Volume Forecast by Application
9.4.1. Sickle Cell Disease
9.4.2. Cancer
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hydroxycarbamide Market Size and Volume Forecast by Type
9.7.1. Capsule
9.7.2. Tablet
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hydroxycarbamide Demand Share Forecast, 2019-2026
10. Latin America Hydroxycarbamide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hydroxycarbamide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hydroxycarbamide Market Size and Volume Forecast by Application
10.4.1. Sickle Cell Disease
10.4.2. Cancer
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hydroxycarbamide Market Size and Volume Forecast by Type
10.7.1. Capsule
10.7.2. Tablet
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hydroxycarbamide Demand Share Forecast, 2019-2026
11. Europe Hydroxycarbamide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hydroxycarbamide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hydroxycarbamide Market Size and Volume Forecast by Application
11.4.1. Sickle Cell Disease
11.4.2. Cancer
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hydroxycarbamide Market Size and Volume Forecast by Type
11.7.1. Capsule
11.7.2. Tablet
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country 11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hydroxycarbamide Demand Share, 2019-2026
12. Asia Pacific Hydroxycarbamide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hydroxycarbamide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hydroxycarbamide Market Size and Volume Forecast by Application
12.4.1. Sickle Cell Disease
12.4.2. Cancer
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hydroxycarbamide Market Size and Volume Forecast by Type
12.7.1. Capsule
12.7.2. Tablet
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hydroxycarbamide Demand Share, 2019-2026
13. Middle East & Africa Hydroxycarbamide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hydroxycarbamide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hydroxycarbamide Market Size and Volume Forecast by Application
13.4.1. Sickle Cell Disease
13.4.2. Cancer
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hydroxycarbamide Market Size and Volume Forecast by Type
13.7.1. Capsule
13.7.2. Tablet
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hydroxycarbamide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hydroxycarbamide Market: Market Share Analysis
14.2. Hydroxycarbamide Distributors and Customers
14.3. Hydroxycarbamide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol Myers Squibb
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Taj Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Beijing Jialin Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Qilu Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Teva Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Cipla
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Zydus Cadila
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. United Biotech
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Par Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Khandelwal Laboratories
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Alkem (Cytomed)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Samarth Pharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. VHB Life Sciences
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook